Emerging BioTalk
  • Home
  • About Us
  • Contact
  • Search
  • Menu

On Demand Webinar: Accelerating the Development of a Virus-Like-Particle Vaccine against COVID-19

July 15, 2022/in Uncategorized /by Tanja Knoll

Insights from a Global Collaboration Accelerating Vaccine Development with an Optimized VLP Platform

The COVID-19 pandemic further emphasized the need for collaboration in the development of urgently needed vaccines and therapeutics. In this webinar, we take you behind the scenes of our collaboration with TechnoVax and Innovative Biotech in which a scalable VLP vaccine platform was optimized  or use in a production facility in Nigeria in response to the need for local production of SARS-CoV-2 vaccines. The flexibility and robustness of the platform will enable its rapid deployment to support the West African pandemic readiness program. Initial development of the VLP process began in late 2019 and by March 2020, was already adapted for production of a SARS-CoV-2 vaccine.

In this presentation we will explore:

  • About building a priceless collaborative network with integrated solutions
  • Virus-Like Particle Vaccines
  • Process Development Overview and Challenges
  • Pre-clinical Results and Next Steps

Register Now:

Webinar Accelerating the Development of a VLP Vaccine against Covid-19

  • Author
  • Recent Posts
Youssef Gaabouri
Associate Director, Head of Sales Middle East & Africa, BioProcess division at Merck Life Sciences
Youssef Gaabouri joined the company in 2009 and has held various positions (Engineering, Biomanufacturing), focused on technologies for downstream processing, for monoclonal antibody and vaccine manufacturing. Before joining the company, he worked at Sanofi Pasteur as Project engineer for Vaccine manufacturing. Youssef holds an Engineering Degree from the Ecole Nationale Supérieure d’Agronomie et des Industries Alimentaires (ENSAIA) de Nancy-France with a focus on Biotechnology Processes.
Latest posts by Youssef Gaabouri (see all)
    • Author
    • Recent Posts
    Naomi Baer
    Business Development Consultant at MilliporeSigma
    Naomi Pintel Baer is a highly regarded Business Development Consultant at our company where she supports early-stage biopharma companies developing scalable upstream and downstream processes for advancing biologics into the clinic. She has more than 30 years of experience in the industry, including in the areas of research, process development, and QC biomonitoring. She began her career at a molecular biologist at Dupont. She graduated with a BS degree in biology from the University of the Sciences in Philadelphia, PA.
    Latest posts by Naomi Baer (see all)
      • Author
      • Recent Posts
      Jose M Galarza
      President and Founder at TechnoVax
      Jose M. Galarza, DVM, PhD, is the CEO and Founder of TechnoVax, Inc. and has more than 30 years of experience in the field of virology and vaccine development. Before founding TechnoVax, he was Principal Scientist and leader of the influenza subunit vaccine development program and member of the vaccine technology advisory board at Wyeth Pharmaceuticals. At Wyeth, he led the team that invented influenza Virus-Like Particle (VLP) vaccine technology. Dr. Galarza received a Doctorate in Veterinary Medicine and a Doctorate in Microbiology from the University of La Plata in Argentina.
      Latest posts by Jose M Galarza (see all)

         

         

        +1
        Share this entry
        • Share on Facebook
        • Share on Twitter
        • Share on LinkedIn
        • Share by Mail
        http://emergingbiotalk.com/wp-content/uploads/2022/07/VLP-webinar.png 321 845 Tanja Knoll http://emergingbiotalk.com/wp-content/uploads/2020/05/emergingbiotalk-header.png Tanja Knoll2022-07-15 04:38:212022-07-15 04:38:21On Demand Webinar: Accelerating the Development of a Virus-Like-Particle Vaccine against COVID-19

        Biotech Resource Hub >>

        • SUBSCRIBE TO OUR BLOG
        • SUBMIT YOUR BLOG POST

        Latest News

        • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
        • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
        • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

        Categories

        • Bioprocessing
        • Biosafety Testing
        • End-to-End Solutions
        • Frontpage Article
        • Gene Therapy
        • Investigator's Brochure
        • News
        • Uncategorized
        • Vaccines
        • Viral Vectors
        • Webinar

        Archives

        • February 2023
        • January 2023
        • December 2022
        • November 2022
        • October 2022
        • September 2022
        • August 2022
        • July 2022
        • May 2022
        • April 2022
        • March 2022
        • February 2022
        • January 2022
        • November 2021
        • October 2021
        • September 2021
        • August 2021
        • July 2021
        • June 2021
        • May 2021
        • April 2021
        • March 2021
        • February 2021
        • January 2021
        • December 2020
        • November 2020
        • October 2020
        • September 2020
        • August 2020
        • July 2020
        • May 2020
        • April 2020
        • SUBSCRIBE TO OUR BLOG
        • SUBMIT YOUR BLOG POST

        Latest News

        • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
        • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
        • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

        Categories

        • Bioprocessing
        • Biosafety Testing
        • End-to-End Solutions
        • Frontpage Article
        • Gene Therapy
        • Investigator's Brochure
        • News
        • Uncategorized
        • Vaccines
        • Viral Vectors
        • Webinar

        Archives

        • February 2023
        • January 2023
        • December 2022
        • November 2022
        • October 2022
        • September 2022
        • August 2022
        • July 2022
        • May 2022
        • April 2022
        • March 2022
        • February 2022
        • January 2022
        • November 2021
        • October 2021
        • September 2021
        • August 2021
        • July 2021
        • June 2021
        • May 2021
        • April 2021
        • March 2021
        • February 2021
        • January 2021
        • December 2020
        • November 2020
        • October 2020
        • September 2020
        • August 2020
        • July 2020
        • May 2020
        • April 2020

        Tags

        applications bioprocessing biotech blazar Congratulations Content education Europe FDA Format gene therapy grant grants Investigator's Brochure molecule new NGS Pharmaceuticals program services symposia tags things Tone VAR2 viral assurance viral clearance virus virus detection winner

        Business Hours

        Our support Hotline is available 24 Hours a day: (555) 343 456 7891

        • Monday-Friday: 9am to 5pm
        • Saturday: 10am to 2pm
        • Sunday: Closed

        Latest News

        • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
        • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
        • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am
        • The Future of BiopharmaDecember 6, 2022 - 4:39 am
        • Last chance: 3rd Annual Startup Symposium – Day 3November 10, 2022 - 5:39 am
        • The Lack of Funding for Women Entrepreneurs Doesn’t Stop Them from Launching – But We Still Have a Long Way to Go – And We Can Help Each Other. Assurea is ROOTING FOR YOU!October 21, 2022 - 8:27 am

        Categories

        • Bioprocessing
        • Biosafety Testing
        • End-to-End Solutions
        • Frontpage Article
        • Gene Therapy
        • Investigator's Brochure
        • News
        • Uncategorized
        • Vaccines
        • Viral Vectors
        • Webinar
        • Author
        • Recent Posts
        Jose M Galarza
        President and Founder at TechnoVax
        Jose M. Galarza, DVM, PhD, is the CEO and Founder of TechnoVax, Inc. and has more than 30 years of experience in the field of virology and vaccine development. Before founding TechnoVax, he was Principal Scientist and leader of the influenza subunit vaccine development program and member of the vaccine technology advisory board at Wyeth Pharmaceuticals. At Wyeth, he led the team that invented influenza Virus-Like Particle (VLP) vaccine technology. Dr. Galarza received a Doctorate in Veterinary Medicine and a Doctorate in Microbiology from the University of La Plata in Argentina.
        Latest posts by Jose M Galarza (see all)
          +1
          © 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. | Privacy Policy | Cookie Settings
          Navigating The Regulatory Maze: Fundamentals for Drug Development Register to Biomanufacturing Training Courses
          Scroll to top

          This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. We use cookies in our website to give you the most relevant experience. By clicking or navigating the site, you are accepting the use of all our cookies according to our Cookie Policy / Privacy Statement. You are free to decide in the Cookie Settings which categories you would like to allow. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy

          Accept All CookiesCookie Settings

          Cookie and Privacy Settings



          Cookie Preferences

          When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about how we use and share your data, please follow this link.
          Privacy Statement

          Necessary

          Always Active
          These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

          Functional

          These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., pop-up notification choices).Changes will take effect once you reload the page.

          Targeting

          These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.

          Confirm My ChoicesAllow AllDisable All

          loading

          Please wait while you are redirected to the right page...

          Please share your location to continue.

          Check our help guide for more info.

          share your location